NovelMed is currently seeking investments or partners to advance its pipeline of anti-complement antibodies. Our lead candidates are now moving to Phase II clinical trial in Q3 of 2023 for PNH. Our primary indication is PNH but given the unique mechanism of action associated with our antibody platform it has the potential to address a number of additional clinical indications. NovelMed is open to discussions for the license of a subset, or the entire complement platform for one or more indications.

Value  Propositions:        
        - Phase I  clinical trial for NM8074 completed in 2022
        - Phase II trial for NM8074 has begun in Q2 2023
        - Phase I clinical trial for NM3086 completed in 2022
        - Advanced  stage antibody platform has the potential to address multiple  indications    
        - Strong intellectual  property with a number of current and pending patents    
        - Undiluted  ownership structure

           We are very interested in licensing our drugs to a partner for their development as novel therapies for rare diseases